Table 1.
Comparison of Gleason upgrading in potential active surveillance patients
| Variable | Group 1 (n = 750) All AS-eligible patients |
Group 1A (n = 453) No Gleason upgrading |
Group 1B (n = 297) Positive Gleason upgrading |
P value/X2 |
|---|---|---|---|---|
| Mean age | 59 ± 6.9 | 58.9 ± 7 | 59.4 ± 6.7 | 0.279 |
| Mean BMI | 27 ± 3.8 | 26.7 ± 3.8 | 27.5 ± 3.7 | 0.004 |
| Mean preop PSA | 4.6 ± 1.9 | 4.4 ± 1.9 | 5.0 ± 1.8 | <0.0001 |
| Total Bx cores | 0.89 | |||
| <18 | 87.9 | 87.7 | 88.1 | |
| ≥18 | 12.1 | 12.3 | 11.9 | |
| Total positive cores | <0.001 | |||
| 1 | 68.3 | 74.6 | 58.6 | |
| 2 | 31.7 | 25.4 | 41.4 | |
| Max % of cancer in biopsy | 0.02 | |||
| ≤5 | 50.9 | 54.5 | 45.5 | |
| >5 | 49.1 | 45.5 | 54.5 | |
| Clinical stage | 0.5 | |||
| T1 | 96.4 | 96 | 97 | |
| T2a | 3.6 | 4 | 3 | |
| HGPIN on Bx | 0.37 | |||
| No | 88.1 | 89.3 | 87.2 | |
| Yes | 11.9 | 10.7 | 12.8 | |
| Prostate volume | 54 ± 23.2 | 55.2 ± 24.1 | 52.1 ± 21.5 | 0.08 |
| Gleason pathology | <0.0001 | |||
| ≤6 | 60.4 | 100 | 0 | |
| 7 | 39.2 | 0 | 99 | |
| 8, 9, 10 | 0.4 | 0 | 1 | |
| pTNM | <0.0001 | |||
| T1–2 | 96.1 | 98.7 | 92.3 | |
| T3–4 | 3.9 | 1.3 | 7.7 | |
| Positive SM rate | 4.7 | 2.4 | 8.1 | <0.0001 |